Predictors of Hepatitis B Cure Using Gene Therapy to Deliver DNA Cleavage Enzymes: A Mathematical Modeling Approach

PLoS Computational Biology

Volumn 9, Issue 7, 2013, Pages

  Schiffer, Joshua T ^a,b   Swan, Dave A ^a   Stone, Daniel ^a   Jerome, Keith R ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOINFORMATICS; CURING; DNA; ENZYME ACTIVITY; GENE THERAPY; VECTORS; VIRUSES;

ANTIVIRAL THERAPY; DNA CLEAVAGE; ENDONUCLEASES; HEPATITIS B; HEPATITIS B VIRUS; MODELING APPROACH; SMALL MOLECULES; VIRAL DNA; VIRAL INFECTIONS; ZINC FINGER NUCLEASE;

REPAIR;

CIRCULAR DNA; CRISPR ASSOCIATED SYSTEM 9 PROTEIN; DNA CLEAVAGE ENZYME; ENDONUCLEASE; ENZYME; MEGANUCLEASE; TAL EFFECTOR NUCLEASE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS VECTOR; ZINC FINGER NUCLEASE;

ARTICLE; DNA CLEAVAGE; DNA REPAIR; ENZYME SUBSTRATE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMORAL IMMUNITY; LIVER CELL; MATHEMATICAL MODEL; NONHUMAN; PHARMACODYNAMICS; PREDICTION; SIMULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 84880799657     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003131     Document Type: Article

References (64)

1. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, et al. (2006) HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 368: 451-458.
2. Schiffer JT, Magaret A, Selke S, Corey L, Wald A, (2011) Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. J Antimicrob Chemother 66: 2593-600.
3. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, et al. (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: 1001-1010.
4. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, et al. (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354: 1011-1020.
5. Siliciano RF, Greene WC, (2011) HIV Latency. Cold Spring Harb Perspect Med 1: a007096.
6. Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ, Marrero JA, et al. (2011) Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 53: 1854-1863.
7. Kock J, Rosler C, Zhang JJ, Blum HE, Nassal M, et al. (2010) Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. PLoS Pathog 6: e1001082.
8. Wald A, Corey L, Cone R, Hobson A, Davis G, et al. (1997) Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest 99: 1092-1097.
9. Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, et al. (2010) HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329: 174-180.
10. Schiffer JT, Aubert M, Weber ND, Mintzer E, Stone D, et al. (2012) Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol 86: 8920-8936.
11. Aubert M, Ryu BY, Banks L, Rawlings DJ, Scharenberg AM, et al. (2011) Successful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI. PLoS One 6: e16825.
12. Cradick TJ, Keck K, Bradshaw S, Jamieson AC, McCaffrey AP, (2010) Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther 18: 947-954.
13. Wilen CB, Wang J, Tilton JC, Miller JC, Kim KA, et al. (2011) Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog 7: e1002020.
14. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, et al. (2008) Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26: 808-816.
15. Hoxie JA, June CH, (2012) Novel Cell and Gene Therapies for HIV. Cold Spring Harb Perspect Med 2: a007179.
16. Kiem HP, Jerome KR, Deeks SG, McCune JM, (2012) Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell 10: 137-147.
17. Stone D, Kiem HP, Jerome KR, (2013) Targeted gene disruption to cure HIV. Curr Opin HIV AIDS 8: 217-223.
18. Perelson A, Essunger P, Cao Y, Vesanen M, Hurley A, et al. (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387: 188-191.
19. Perelson AS, Ribeiro RM, (2004) Hepatitis B virus kinetics and mathematical modeling. Semin Liver Dis 24 Suppl 1: 11-16.
20. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, et al. (2008) Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 14: 762-766.
21. Shen L, Rabi SA, Siliciano RF, (2009) A novel method for determining the inhibitory potential of anti-HIV drugs. Trends Pharmacol Sci 30: 610-616.
22. Deng K, Zink MC, Clements JE, Siliciano RF, (2012) A quantitative measurement of antiviral activity of anti-HIV-1 drugs against SIV infection: dose response curve slope strongly influences class-specific inhibitory potential. J Virol 86 (20) (): 11368-72.
23. Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, et al. (2012) A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med 18: 446-451.
24. Shen L, Rabi SA, Sedaghat AR, Shan L, Lai J, et al. (2011) A Critical Subset Model Provides a Conceptual Basis for the High Antiviral Activity of Major HIV Drugs. Sci Transl Med 3: 91ra63.
25. Sampah ME, Shen L, Jilek BL, Siliciano RF, (2011) Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc Natl Acad Sci U S A 108: 7613-7618.
26. Addison WR, Walters KA, Wong WW, Wilson JS, Madej D, et al. (2002) Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 76: 6356-6363.
27. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, et al. (1995) The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 69: 3350-3357.
28. Nuriya H, Inoue K, Tanaka T, Hayashi Y, Hishima T, et al. (2010) Detection of hepatitis B and C viruses in almost all hepatocytes by modified PCR-based in situ hybridization. J Clin Microbiol 48: 3843-3851.
29. Yaginuma K, Kobayashi H, Kobayashi M, Morishima T, Matsuyama K, et al. (1987) Multiple integration site of hepatitis B virus DNA in hepatocellular carcinoma and chronic active hepatitis tissues from children. J Virol 61: 1808-1813.
30. Yaginuma K, Kobayashi M, Yoshida E, Koike K, (1985) Hepatitis B virus integration in hepatocellular carcinoma DNA: duplication of cellular flanking sequences at the integration site. Proc Natl Acad Sci U S A 82: 4458-4462.
31. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, et al. (2004) Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126: 1750-1758.
32. Laras A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ, (2006) Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 44: 694-702.
33. Zhang YY, Zhang BH, Theele D, Litwin S, Toll E, et al. (2003) Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver. Proc Natl Acad Sci U S A 100: 12372-12377.
34. Ciupe SM, Ribeiro RM, Nelson PW, Perelson AS, (2007) Modeling the mechanisms of acute hepatitis B virus infection. J Theor Biol 247: 23-35.
35. Yan H, Zhong G, Xu G, He W, Jing Z, et al. (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 1: e00049.
36. Akache B, Grimm D, Pandey K, Yant SR, Xu H, et al. (2006) The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 80: 9831-9836.
37. Kalyuzhniy O, Di Paolo NC, Silvestry M, Hofherr SE, Barry MA, et al. (2008) Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A 105: 5483-5488.
38. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, et al. (2008) Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397-409.
39. Wu Z, Miller E, Agbandje-McKenna M, Samulski RJ, (2006) Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol 80: 9093-9103.
40. Summerford C, Samulski RJ, (1998) Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72: 1438-1445.
41. Shen S, Bryant KD, Brown SM, Randell SH, Asokan A, (2011) Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem 286: 13532-13540.
42. Xiao X, Li J, Samulski RJ, (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72: 2224-2232.
43. Sommer JM, Smith PH, Parthasarathy S, Isaacs J, Vijay S, et al. (2003) Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol Ther 7: 122-128.
44. Fan PD, Dong JY, (1997) Replication of rep-cap genes is essential for the high-efficiency production of recombinant AAV. Hum Gene Ther 8: 87-98.
45. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, et al. (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365.
46. Nonnenmacher M, Weber T, (2012) Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther 19: 649-658.
47. Stone D, (2010) Novel viral vector systems for gene therapy. Viruses 2: 1002-1007.
48. Rapti K, Louis-Jeune V, Kohlbrenner E, Ishikawa K, Ladage D, et al. (2012) Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther 20: 73-83.
49. Wang L, Calcedo R, Bell P, Lin J, Grant RL, et al. (2011) Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther 22: 1389-1401.
50. Hurlbut GD, Ziegler RJ, Nietupski JB, Foley JW, Woodworth LA, et al. (2010) Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol Ther 18: 1983-1994.
51. Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD, (2000) Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol 74: 1524-1532.
52. Riviere C, Danos O, Douar AM, (2006) Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther 13: 1300-1308.
53. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, et al. (2004) Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 78: 6381-6388.
54. Gao G, Alvira MR, Somanathan S, Lu Y, Vandenberghe LH, et al. (2003) Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci U S A 100: 6081-6086.
55. Pierson T, McArthur J, Siliciano RF, (2000) Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 18: 665-708.
56. Wang K, Lau T, Morales M, Mont E, Straus S, (2005) Laser-capture microdissection: refining estimates of the quantity and distribution of latent herpes simplex virus 1 and varicella-zoster virus DNA in human trigeminal Ganglia at the single-cell level. J Virol 79: 14079-14087.
57. Locarnini S, Zoulim F, (2010) Molecular genetics of HBV infection. Antivir Ther 15 Suppl 3: 3-14.
58. Rodriguez-Inigo E, Mariscal L, Bartolome J, Castillo I, Navacerrada C, et al. (2003) Distribution of hepatitis B virus in the liver of chronic hepatitis C patients with occult hepatitis B virus infection. J Med Virol 70: 571-580.
59. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, et al. (2001) Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7: 927-933.
60. Tsuge M, Hiraga N, Takaishi H, Noguchi C, Oga H, et al. (2005) Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 42: 1046-1054.
61. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183-188.
62. Chun TW, Justement JS, Pandya P, Hallahan CW, McLaughlin M, et al. (2002) Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J Infect Dis 185: 1672-1676.
63. Wagner TA, Tobin NH, McKernan JL, Xu M, Melvin AJ, et al. (2009) Increased mutations in Env and Pol suggest greater HIV-1 replication in sputum-derived viruses compared with blood-derived viruses. AIDS 23: 923-928.
64. Nickle DC, Jensen MA, Shriner D, Brodie SJ, Frenkel LM, et al. (2003) Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments. J Virol 77: 5540-5546.